Indeed, it is known that the antiproliferative effect of ERβ is accompanied by downregulation in the expression of CYCLINE D1 (CCND1), a cell cycle regulator overexpressed in epithelial, ovarian, and breast cancers [7,8,9,10]. Here, CCND1 is linked to breast cancer.